Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Histology microscope image of motor unit synapse of muscle fibers (100x)

Duchenne muscular dystrophy

Duchenne Muscular Dystrophy Space on Cusp of Pivotal Era

While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several companies including Wave, Dyne and Avidity are looking to answer the call with investigational therapies targeting greater efficacy and broader reach.

January 27, 2025

8 min read

Kate Goodwin

Editorial

Trump’s First Week: A Binge-Worthy Show, If Nothing Else

Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health agencies, among other moves that have sent waves through the biopharma industry.

January 24, 2025

4 min read

Jef Akst

Facade of Novo Nordisk's office in Fremont, California

Obesity

Novo Rebounds as Next-Gen Obesity Drug Elicits up to 22% Weight Loss

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% weight reduction.

January 24, 2025

2 min read

Tristan Manalac

Phase III

Merck’s Keytruda Combo Fails to Extend Survival in Phase III GI Cancer

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against its limits after racking up around 50 approvals since getting its first FDA nod in September 2014.

January 24, 2025

2 min read

Annalee Armstrong

Mechanical weight scale, body mass control concept : Bathroom scale on pale blue wood background. Analog scale operated with spring that pressure is calibrated to translate tension into a mass readout.

Obesity

Obesity-Focused Aardvark Therapeutics Files IPO to Advance Lead Candidate

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

January 24, 2025

1 min read

Dan Samorodnitsky

Pictured: Loaded syringe and opioids_iStock, Darwi

Legal

Purdue Pharma, Sacklers Settle Opioid Lawsuits For $7.4B

The settlement is the largest deal to date with the people primarily who played an “instrumental role” in driving the opioid crisis, according to the office of Massachusetts Attorney General Andrea Joy Campbell.

January 24, 2025

2 min read

Tristan Manalac

Government

Senate Lines Up RFK Jr. Confirmation Hearing Amid Mounting Criticism

Robert F. Kennedy, Jr.’s recent disclosures have revealed several potential conflicts of interest, including investments in two biopharma companies.

January 24, 2025

2 min read

Tristan Manalac

Brain shaped white jigsaw puzzle on blue background. Mental health and problems with memory.

Alzheimer’s disease

Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II

Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.

January 23, 2025

2 min read

Dan Samorodnitsky